TJP2

Across TCGA pan-cancer cohorts, TJP2 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of TJP2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TJP2 RNA is repressed in tumor relative to normal tissue. In most cancer types TJP2 is over-expressed in tumor, although a few such as KIRC and LUAD show the opposite, repressed pattern.

KIRC, LUAD, and COAD are the cancer types where TJP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TJP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.759	<.001	12	view →
LUAD	Female	II,III,IV	−1.097	<.001	7	view →
COAD	Male	II,III,IV	+0.601	<.001	6	view →
BRCA	Female	All	−0.559	<.001	6	view →
LUSC	All	All	−0.686	<.001	5	view →
KICH	All	All	−0.765	.005	4	view →
LIHC	All	All	−0.502	.002	3	view →
CHOL	Male	All	+1.049	.035	2	view →
HNSC	All	All	+0.357	.022	2	view →
STAD	Female	III,IV	−1.045	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

TJP2–KIRC

Open the KIRC breakdown →